InvestorsHub Logo
Followers 29
Posts 4039
Boards Moderated 0
Alias Born 11/16/2016

Re: None

Monday, 05/23/2022 7:48:13 AM

Monday, May 23, 2022 7:48:13 AM

Post# of 1106
The damn may well have busted!

“The clinical-stage biotech, ImmunoGen (NASDAQ:IMGN) announced on Monday that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its ovarian cancer therapy mirvetuximab soravtansine under priority review.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMGN News